HK:2269 WuXi Biologics (Cayman) Inc

WuXi Biologics (Cayman) Inc., an investment holding company, provides discovery, research, development, and manufacturing of biologics services. It offers clinical and commercial manufacturing, assay, formulation and process development, assay and process validation, protein, monoclonal antibodies and cGMP drug substances manufacturing, lot release testing, stability studies, drug product formulation, fill and finish, and regulatory support services. The company also provides consultation services for biopharmaceutical technology, sales and marketing, and international sales contracting service; and produces and sells medicals. It serves pharmaceutical and biotechnology companies. WuXi Biologics (Cayman) Inc. has a strategic collaboration with Bioasis Technologies Inc. to develop and manufacture xB3-001 to treat cancer; CANbridge Pharmaceutical Inc. to develop and commercialize a portfolio of iotherapeutics for the treatment of rare diseases; ABL Bio Corporation to develop bispecific antibodies; AC Immune SA for biologics discovery, development, and manufacturing; and Oxford BioTherapeutics for developing bispecific antibodies. The company was founded in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.This company has ADRs that trade in the U.S. as the symbol WXXWY.

103.40 HKD
As of 11/26/2021


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  China
Country of incorporation:  Cayman Islands
IPO date:  06/13/2017
Stock exchange:    Hong Kong Exchange
Exchange country:   Hong Kong
Market cap:   438,221,602,816 HKD
Current dividend yield:   0.00%
CUSIP:    G97008109
ISIN:        KYG970081090
Sedol:      BZ3C3R5

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy